Allogene Therapeutics Inc (NAS:ALLO)
$ 2.99 -0.01 (-0.33%) Market Cap: 625.25 Mil Enterprise Value: 269.70 Mil PE Ratio: 0 PB Ratio: 1.22 GF Score: 34/100

Q4 2022 Allogene Therapeutics Inc Earnings Call Transcript

Feb 28, 2023 / 10:00PM GMT
Release Date Price: $6.35 (+0.32%)
Operator

Good day, ladies and gentlemen, and thank you for standing by. Welcome to Allogene Therapeutics' Fourth Quarter and Year-End 2022 Earnings Conference Call. (Operator Instructions)

I would now like to turn the call over to Christine Cassiano, Chief Communications Officer. Ms. Cassiano, please go ahead.

Christine Cassiano
Allogene Therapeutics, Inc. - Executive VP, Chief Corporate Affairs & Brand Strategy Officer

Thank you, operator, and welcome to our call. Today, after market closed, Allogene issued a press release that provides a business update and financial results for the fourth quarter and full year 2022. This press release and today's webcast are both available on our website. Following our prepared remarks, we will host a Q&A session. We ask you to limit your questions to one per person, as we will keep this call to an hour and do our best to get to as many as possible.

Joining me today are Dr. David Chang, President and Chief Executive Officer; Dr. Zachary Roberts, Executive Vice President of Research and Development; and Dr.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot